Passage Bio (PASG) Competitors $8.52 +0.01 (+0.12%) Closing price 03:59 PM EasternExtended Trading$8.57 +0.05 (+0.65%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. ORMP, MGX, CNTX, SLGL, IPA, IMUX, ANEB, HOWL, ADAG, and PLRXShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Oramed Pharmaceuticals (ORMP), Metagenomi (MGX), Context Therapeutics (CNTX), Sol-Gel Technologies (SLGL), ImmunoPrecise Antibodies (IPA), Immunic (IMUX), Anebulo Pharmaceuticals (ANEB), Werewolf Therapeutics (HOWL), Adagene (ADAG), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Its Competitors Oramed Pharmaceuticals Metagenomi Context Therapeutics Sol-Gel Technologies ImmunoPrecise Antibodies Immunic Anebulo Pharmaceuticals Werewolf Therapeutics Adagene Pliant Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability. Do analysts recommend ORMP or PASG? Passage Bio has a consensus price target of $75.67, suggesting a potential upside of 788.11%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Passage Bio 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders hold more shares of ORMP or PASG? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ORMP or PASG more profitable? Oramed Pharmaceuticals' return on equity of -19.37% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -19.37% -18.28% Passage Bio N/A -103.87%-59.95% Does the media prefer ORMP or PASG? In the previous week, Passage Bio had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for Passage Bio and 3 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.83 beat Passage Bio's score of 0.47 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ORMP or PASG? Oramed Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Which has better valuation & earnings, ORMP or PASG? Oramed Pharmaceuticals has higher revenue and earnings than Passage Bio. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M69.46-$19.06M-$0.35-6.49Passage BioN/AN/A-$64.77M-$18.16-0.47 SummaryOramed Pharmaceuticals and Passage Bio tied by winning 7 of the 14 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.09M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-0.4722.9285.4427.36Price / SalesN/A270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book0.4310.5512.426.82Net Income-$64.77M-$52.58M$3.32B$276.89M7 Day Performance2.90%1.09%1.01%0.27%1 Month Performance22.59%16.09%10.75%8.31%1 Year Performance-26.68%18.41%76.20%35.60% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio3.6223 of 5 stars$8.52+0.1%$75.67+788.1%-29.2%$27.09MN/A-0.47130News CoverageORMPOramed Pharmaceuticals1.2232 of 5 stars$2.45+0.4%N/A-0.8%$100.05M$1.34M-7.0010MGXMetagenomi3.4052 of 5 stars$2.69+1.5%$10.00+271.7%+48.7%$99.46M$52.29M-1.14236Gap UpCNTXContext Therapeutics3.2332 of 5 stars$1.21+10.0%$5.20+329.8%-30.7%$98.68MN/A-3.367Gap UpHigh Trading VolumeSLGLSol-Gel Technologies0.616 of 5 stars$42.90+23.3%N/A+501.1%$96.95M$23.93M-34.8850High Trading VolumeIPAImmunoPrecise Antibodies1.0467 of 5 stars$2.10+8.5%$4.00+90.9%+263.3%$96.68M$17.59M-3.0880Gap UpIMUXImmunic2.2225 of 5 stars$0.94-3.9%$9.50+910.6%-41.9%$96.51MN/A-1.0070ANEBAnebulo Pharmaceuticals2.9792 of 5 stars$2.33+0.9%$5.50+136.1%+34.4%$94.91MN/A-8.964Gap UpHOWLWerewolf Therapeutics3.4663 of 5 stars$2.03-1.0%$8.00+294.1%-14.8%$93.74M$1.88M-1.2440News CoverageGap UpADAGAdagene2.5261 of 5 stars$1.99+0.5%$7.00+251.8%-16.7%$93.32M$100K0.00260PLRXPliant Therapeutics4.0873 of 5 stars$1.49-2.0%$8.19+449.5%-89.0%$93.31M$1.58M-0.4490 Related Companies and Tools Related Companies ORMP Alternatives MGX Alternatives CNTX Alternatives SLGL Alternatives IPA Alternatives IMUX Alternatives ANEB Alternatives HOWL Alternatives ADAG Alternatives PLRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
